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Recently, data and news about rising numbers of leprosy cases in some low endemic countries, as 
well as in certain areas of high-burden countries, have become prominent 1. This increase leads us to 
reflect upon changes in transmission patterns and difficulties regarding interventions strategies for 
leprosy control.
Leprosy is classified as a neglected tropical disease (NTD) targeted for elimination 2. The goal of 
elimination as a public health problem was agreed upon by the Member States of the World Health 
Organization (WHO) in 1991 3. Since the resolution, many countries have revised their leprosy strat-
egies including a rigorous review and updating of databases, standardized declaration of cure upon 
multi-drug therapy (MDT) completion according to official protocols with reduced treatment time 4 
etc. Additionally, countries invested considerable efforts in active case finding, including campaigns, 
decentralization of care, definition of priority areas for interventions and integration of activities 
with other NTDs 5. More recently, integration with other chronic infectious diseases has also been 
explored 5. Of note, even Mycobacterium leprae transmission prediction models suggest that case detec-
tion needs to be increased to reduce disease burden and achieve reduced transmission 6.
It is generally accepted that there are no sudden leprosy outbreaks due to the long incubation 
period and the slow evolution of the disease, which mean that the patients being diagnosed today 
were infected several years ago 7. Consequently, changes in the trend of incidence indicators are slow, 
except for the effects of operational factors. In developing countries, active case finding efforts in vul-
nerable populations typically result in the detection of new patients, with the most vulnerable groups 
being the contacts of index patients, including domestic, neighbor and social contacts 8, whose risk is 
dependent on proximity and contact duration, leprosy type of the index patient, and blood relation-
ship. There is now also consensus that M. leprae circulate in the environment of endemic areas. This 
ecological component has recently been explored in more detail, but its epidemiological significance 
remains unclear 9. Other etiological agents such as M. lepromatosis have also been described 10.
Treatment for leprosy has been made available for decades through the WHO to endemic coun-
tries, free of charge. Reported stock-outs of the medication are due to logistical issues. To complement 
the standard MDT, locally procured drugs are needed for special conditions, and to control so-called 
leprosy reactions.
To sum up, by “leprosy” we are referring to a historically endemic, treatable, and curable infec-
tious disease. Therefore, the basic surveillance recommendations are to ensure early diagnosis and 
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prompt treatment, including through contact trancing to effectively search for new cases, reducing 
the chain of transmission. Furthermore, poor nutrition and living conditions have also been identified 
as determinants for leprosy, and recent studies have highlighted and quantified its association with 
poverty 11. Considering the current economic situation and prevalence of conflicts and associated 
large-scale and long-distance migration resulting in reduced income and deteriorating living condi-
tions 12, the number of leprosy cases is likely to increase in certain areas while the global aggregate 
might fall slowly and gradually. Thus, new technologies and approaches, including revised therapeu-
tic protocols, pre- and post-exposure prophylaxis with vaccines and drugs and the development of 
diagnostic tests and surveillance, are essential to reduce M. leprae transmission and leprosy. In 2018, 
the WHO 7 published the first Guideline for the Diagnosis, Treatment and Prevention of Leprosy based 
on scientific evidence. For all three dimensions covered, there are promising initiatives 13 yet the 
absence of fully performant serological tests with potential to be included in the routine of health 
services is still a limitation. The main diagnosis-related recommendation concerns the qualification 
of staff performing clinical diagnosis, confirmative bacilloscopy and histopathological tests. With 
regard to treatment, uniform multidrug-therapy (UMDT) using the same 3-drug regimen including 
rifampicin, dapsone and clofazimine for all leprosy patients, with a duration of treatment of 6 months 
for paucibacillary (PB) leprosy and of 12 months for multibacillary (MB) leprosy is recommended. 
Regarding disease prevention, single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) 
comprising appropriate doses (600mg for adults) is recommended for domestic, neighbor and social 
contacts. Unfortunately, there is no diagnostic test available to detect M. leprae infection, identifying 
at-risk groups with reasonably high sensitivity. The titers of IgM and IgG antibodies against M. leprae 
vary according to the disease operational classification. IgM may be detected by enzyme-linked 
immunosorbent assays (ELISAs) based on phenolic glycolipid I (PGL-I) or natural disaccharide octyl 
bovine serum albumin (ND-O-BSA) as antigens; IgG response can be detected by an ELISA based on 
lipid droplet protein 1 (LID-1). A recent metanalyses showed no advantages in the overall estimated 
sensitivity for isolated LID-1 compared to PGL-I or ND-O-BSA 14. In terms of outlook, validating 
and introducing serological tests with anti-PGL-I and natural disaccharide octyl and lipid droplet 
protein 1 (NDO-LID) combination for field use might support the diagnosis 14. Although additional 
biomarkers have been identified, validating and implementing their use remain challenging, and there 
is no reliable and rapid point-of-care (POC) test on the horizon. The main difficulty of existing tests 
is their unsatisfactory performance, especially for PB disease. This justifies the high expectations on 
developing more sensitive and specific tests based on T-cells and molecular technologies with a focus 
on PCR 15. In the longer term, the combination of improved imaging techniques, artificial intelli-
gence and telemedicine might increase access to diagnosis. Complementing treatment, an important 
concern is the establishment of an effective drug resistance surveillance network, although current 
findings show a low prevalence of primary and secondary drug resistance 16. 
Studies that seek to reduce treatment time or replace current medications are now underway 17. 
With regard to prevention and to complement the findings of the Leprosy Post-Exposure Prophylaxis 
(LPEP) program which demonstrated feasibility and acceptability of SDR-PEP across eight countries 
(Brazil, Cambodia, India, Indonesia, Myanmar, Nepal, Sri Lanka, and Tanzania) 18,19 as well as cost-
effectiveness 20, the benefits of adding BCG vaccination to SDR should be explored. Given at birth, 
BCG has been associated with an 80% (95%CI: 50%-92%) risk reduction of developing leprosy if SDR-
PEP is administered as post-exposure prophylaxis. BCG is particularly valuable for reducing the risk 
of MB cases while its effect on PB is less evident 21. Moreover, there is an active discussion on revac-
cination risks and benefits: while it may increase protection, it might cause accelerated manifestation 
of PB cases 22. Current evidence suggests maintaining BCG at birth until the development of a more 
effective option. A protein sub-unit vaccine has been developed by the Infectious Diseases Research 
Institute (IDRI) in Seattle, United States. LepVax as it is known, has completed phase I trials in the 
United States and will begin further trials shortly 23,24. Clinical trials under study with LepVax are also 
advancing, with the vaccine showing potential for both reducing the risk of illness and neural damage 
for infected patients 23. The combination of immuno- and chemoprophylaxis would have a big effect 
on both infection and morbidity 13. It can be assumed that the preventive effect among contacts will 
increase when combining LepVax with chemoprophylaxis. LepVax also has the advantage over BCG 
that as a subunit vaccine it can potentially be given at the same time as antibiotics 24,25. It is worth 
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mentioning that both vaccination and PEP depend on extensive contact tracing 18,19. Another per-
sistent challenge is the great number of patients with bacteriologically documented cure that present 
noticeable physical disabilities, affecting their economic, emotional and social life. Regardless of age, 
the risk of worsening physical disability after discharge from therapy is at least 30%, after 10 years 
21. In other words, thousands of former patients continue to require assistance in terms of care and 
prevention of disabilities.
Unlike several others NTDs, such as onchocerciasis and lymphatic filariasis, the procedures 
for verifying leprosy elimination are still to be developed. This is highly relevant as, although some 
regions are experiencing an increase in the number of diagnosed cases, many countries report very 
few cases, and possibly transmission has even ceased in some of them. Whether for reducing the bur-
den of the disease or certifying its elimination, maintaining routine activities and establishing a robust 
surveillance-response system is crucial, but current infrastructure is insufficient in many places.
Interrupting M. leprae transmission and eliminating leprosy will depend on the decision of manag-
ers and funders of control programs, including Ministries of Health, to use all technologies available 
and recommended. Furthermore, partnerships and close collaboration between research institutions, 
international normative agencies, such as WHO, national health authorities, non-governmental orga-
nizations (NGOs), and funding partners are needed to implement and sustain innovations in routine 
health services and to progressively introduce the forthcoming new tools.
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